Floatz logo

Bimiralisib

Non-Hodgkin Lymphoma

PIQUR Therapeutics AGSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

411 Active assets in the Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Fludarabine
Marcela V. Maus, M.D.,Ph.D.
Phase 3BBB

View all 50 →

Same molecule, other indications

Bimiralisib is also rated in:

primary central nervous system lymphomaDormant
B
Indicative ·
57 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →